InvestorsHub Logo
Followers 25
Posts 1336
Boards Moderated 0
Alias Born 11/15/2016

Re: None

Wednesday, 01/10/2018 1:36:26 PM

Wednesday, January 10, 2018 1:36:26 PM

Post# of 203909
Owcp, under the radar and undervalued. Problem is, there really not well known. I believe upon publicly announcing safety trials of the cream and tablet success, and also announcing there moving forward with phase 2 trials on both will ultimately get attention from other investors.

I also suspect an announcement of cancellation of mediq and someone much better will be announced upon completion of the safety trial on the cream. I also believe this better option has requested a safety trial done on the tablet to get it to market.

Just a few of things in 2018 that could easily become real.

Check out the rise of GWPH and how long there study on epilepsy is taking from start til now, and look at there stock price as developments rolled in to get a better understanding of where we could be this year and beyond with not one, but two major trials taking place. And a third lagging just a little behind them.

MM, tough to say, there always pretty quite on that study.